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Abstract 
Gliomas are the most frequent brain tumors worldwide. Gliomas make up about 30% of 
all brain and central nervous system tumors, and 80% of all malignant brain tumors. 
Diagnosis of the glioma tumor type and its grade is a most essential step in order to 
suggest a right treatment for the glioma patients. 
We present a comprehensive study of the different types of the tumors with a low burden 
in plasma matched with the cfDNA extracted from a clinical cohort of patients' plasma in 
order to find unique tumor mutations as biomarkers. We successfully detected the glioma 
specific mutations for the highly frequently mutated genes such as IDH2, PDGFRA, 
NOTCH1, PIK3R1 and 30 other genes. We identified the particular mutations of the 
cfDNA isolated from the plasma of the glioma patients, followed by the DNA-sequencing 
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and our predictive bioinformatics analysis. We have collected the matched tumor and 
cfDNA mutations to uncover the tumor grade as well as its heterogeneity using our 
unique measurement of the mutations coverage by the DNA-seq reads. Moreover, we 
used our previously published methods to uncover unique fusions in the glioma patients 
and its alterations in the protein-protein interactions networks to understand the tumor 
prognosis. For the best of our knowledge, our study is the most advanced study in the 
field of the liquid biopsy for the brain cancer tumors, and it will provide a quick and safe 
non-invasive diagnostic method for the glioma patients, as it uncovers the tumour sub-
types using unique biomarkers. This will provide the best personalized treatment for the 
highly complicate disease and will eventually bypass the existing "wait-and- see" method 
for prognosis.  
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